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Abstract
Congenital hepatic fibrosis has been described as a lethal disease with monogenic autosomal recessive inheritance in the
Swiss Franches-Montagnes horse breed. We performed a genome-wide association study with 5 cases and 12 controls and
detected an association on chromosome 20. Subsequent homozygosity mapping defined a critical interval of 952 kb
harboring 10 annotated genes and loci including the polycystic kidney and hepatic disease 1 (autosomal recessive) gene
(PKHD1). PKHD1 represents an excellent functional candidate as variants in this gene were identified in human patients with
autosomal recessive polycystic kidney and hepatic disease (ARPKD) as well as several mouse and rat mutants. Whereas most
pathogenic PKHD1 variants lead to polycystic defects in kidney and liver, a small subset of the human ARPKD patients have
only liver symptoms, similar to our horses with congenital hepatic fibrosis. The PKHD1 gene is one of the largest genes in the
genome with multiple alternative transcripts that have not yet been fully characterized. We sequenced the genomes of an
affected foal and 46 control horses to establish a comprehensive list of variants in the critical interval. We identified two
missense variants in the PKHD1 gene which were strongly, but not perfectly associated with congenital hepatic fibrosis. We
speculate that reduced penetrance and/or potential epistatic interactions with hypothetical modifier genes may explain the
imperfect association of the detected PKHD1 variants. Our data thus indicate that horses with congenital hepatic fibrosis
represent an interesting large animal model for the liver-restricted subtype of human ARPKD.
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Introduction
Autosomal recessive polycystic kidney disease (ARPKD) has an
incidence of about 1:20,000 in humans [1]. It is caused by variants
in the polycystic kidney and hepatic disease 1 (autosomal recessive)
gene (PKHD1). More than 500 different potentially pathogenic
variants in the human PKHD1 gene have been described, and
there is considerable variation in the clinical phenotype and age of
onset ([1,2], http://www.humgen.rwth-aachen.de/index.php). Pa-
tients carrying two truncating PKHD1 mutations typically die
perinatally, whereas patients with residual PKHD1 function
typically have less severe disease, which predominantly affects
the kidney and the liver. A small subset of patients with PKHD1
mutations only show hepatic disease [2,3].
The PKHD1 protein probably has an essential role in the
primary cilia of tubular epithelial cells, which are required as
mechanosensors and regulate Ca2+ influx. PKHD1 probably
directly interacts with polycystin 2 (PKD2), but its precise function
and the role of its many different isoforms are unknown [4]. The
PKHD1 gene is very complex and spans about 500 kb with
multiple alternative transcripts. The best studied human PKHD1
transcript comprises 67 exons, has an open reading frame of
12,222 nucleotides, and encodes a protein of 4,074 amino acids,
which has also been termed fibrocystin or polyductin [5,6].
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Several rodent models of ARPKD have been described. The
polycystic rat (PCK) carries a spontaneous splice site mutation in
the Pkhd1 gene and is characterized by cyst formation in kidney
and liver. There are also several targeted mouse mutants available
including one that exclusively shows cystic biliary dysgenesis
without kidney alterations [7–10]. The occurrence of similar
diseases affecting exclusively the liver has been reported in monkey
[11], and different sporadic cases in domestic animal species like
cattle [12,13], cat [14], dog [15], and horse [16,17]. We previously
identified 30 foals with liver lesions compatible with congenital
hepatic fibrosis in a retrospective study [17,18]. Anamnestic data
revealed clinical signs of severe liver injury in most affected
animals [16,17]. Pathologic examination showed severely en-
larged, firm livers with thin-walled cysts. Histologically, the livers
showed diffuse porto-portal bridging fibrosis with many small,
irregularly formed and sometimes cystic bile ducts [18]. All foals
belonged to the Swiss Franches-Montagnes breed. Pedigree
analysis revealed that the affected animals could be traced back
to one stallion [18]. These results strongly suggest that congenital
hepatic fibrosis in Swiss Franches-Montagnes horses is an
autosomal recessively inherited genetic defect.
During the last six years seven inbred foals were born with
congenital liver fibrosis and submitted for genetic investigations.
The aim of the present study was to identify the assumed genetic
cause for the condition using a positional approach and next
generation sequencing in order to develop a genetic test to prevent
further at risk matings.
Results
Congenital liver fibrosis in Franches-Montagnes horses
Between the years 2008 and 2013, we recruited a total of 7
Franches-Montagnes foals, 5 males and 2 females, aged 3 weeks to
12 months, with clinical signs of severe liver injury (Figure 1). The
parents of all cases were clinically inconspicuous. In 5 out of these
7 foals the quality of tissue or blood samples and the extracted
DNA was sufficient for genotyping with SNP chips. The parents of
these 5 foals could be traced, both on the maternal and the
paternal lines over 3 to 7 generations, to a single common male
ancestor (Elu) born in 1964 (Figure 2). Therefore, we concluded
that a recessively inherited mutation was most likely, in agreement
with our earlier studies [18]. Formalin-fixed paraffin-embedded
liver samples from the earlier study were available and we
successfully extracted DNA from 13 of these affected foals.
Two of the recent cases were admitted to the horse clinic of the
University of Bern for in-depth clinical examination (Figure 1).
They were in a reduced body shape and showed depressed
behavior. Their abdomens were enlarged and feces were yellowish
and of an oily consistence. Trans-abdominal ultrasound revealed
an increased liver size with distinct cystic hypo-echoic lesions.
Hematology showed a severe leukocytosis due to a severe
neutrophilia. The laboratory chemistry showed extremely high
liver bile acids. Both patients were euthanized and subjected to a
necropsy.
Histopathological examination of all affected foals revealed that
the liver showed diffuse porto-portal bridging fibrosis with many
small, irregularly formed and sometimes cystic bile ducts
(Figure 1C) similar to the earlier series of 30 reported cases of
congenital liver fibrosis in the Franches-Montagnes breed [18].
Mapping to a region on ECA 20 containing PKHD1 as
functional candidate gene
We genotyped 65,157 SNPs on 5 affected foals and 12 non-
affected Franches-Montagnes horses. After removing non-infor-
mative markers (MAF,0.1) and markers with call rates below
90%, we retained 38,394 SNPs for an allelic genome-wide
association study (GWAS). The genomic inflation factor in this
analysis was 1.33, indicating stratification due to the usage of
closely related animals (Figure 2). The analysis revealed a single
associated SNP, BIEC2-564517, at position 49,643,575 on
chromosome 20. The raw p-value of the association was
5.561029. This exceeds the Bonferroni-corrected significance
threshold (pBonf = 0.00021) and also an empirical significance
threshold determined after 100,000 permutations of the pheno-
types (pgenome = 0.00011, Figure 3).
Based on the pedigree records we hypothesized that the affected
foals were most likely inbred and related to a single founder animal
(Figure 2). Under this scenario the affected individuals were
expected to be identical by descent for the causative mutation and
flanking chromosomal segments. We therefore analyzed the cases
for the presence of a region of homozygosity with simultaneous
allele sharing near the associated SNP on chromosome 20. In this
region all 5 cases indeed were homozygous, and shared identical
alleles over 31 consecutive SNP markers. This segment delineates
a critical interval of 952 kb between the closest heterozygous
markers on either side of the shared homozygous block
(Chr20:49,164,218–50,115,936; Figure 3C).
According to the NCBI annotation release 101 of the EquCab2
assembly the critical interval contains 6 annotated protein coding
genes (PKHD1, IL17A, IL17F, MCM3, PAQR8, EFHC1), 2
microRNA genes (MIR206-2, MIR133B) and 2 uncharacterized
loci (LOC102148758, LOC102148781). A careful inspection of
these genes and database searches of their presumed function
revealed the polycystic kidney and hepatic disease 1 gene
(PKHD1) as an excellent functional candidate gene for congenital
hepatic fibrosis in horses. Mutations in this gene cause autosomal
recessive polycystic kidney (ARPKD) disease in humans, also
known as polycystic kidney and hepatic disease 1
(OMIM#263200).
Whole genome re-sequencing reveals no perfectly
associated DNA variant
We opted to sequence the whole genome of one affected foal
and an obligate heterozygous carrier sire of another case to
generate a comprehensive list of variants with respect to the equine
reference genome from a non-affected Thoroughbred horse.
Due to the recessive inheritance and the fatal effect of the
mutation, we initially hypothesized that most likely a loss of
function mutation affecting the coding sequence of PKHD1 would
be responsible for the congenital hepatic fibrosis phenotype.
Within the mapped 952 kb interval, we identified 16 non-
synonymous variants (Table 1; Figure S1). Two of these are most
likely due to frame-shift errors in the genome reference sequence
as the computer-predicted RefSeq transcript (XM_001498967.4)
contains two additional nucleotides compared to the genome
reference. The remaining 14 non-synonymous variants were all
missense variants within the PKHD1 gene. All 14 non-synony-
mous variants were homozygous in the sequenced case and
heterozygous in the sequenced obligate carrier.
We then compared the sequence data from the affected foal to
whole genome sequences from 28 non-affected Franches-Mon-
tagnes horses and 18 horses of various other breeds (Table S1). All
of the 14 non-synonymous variants also occurred in control horses
of other breeds, 12 of them even in homozygous state. Two out of
the 14 non-synonymous variants were only found in heterozygous
state in the control horses.
We then focused on these two variants, PKHD1:c.6112C.T
and PKHD1:c.6845T.A, predicted to cause the non-conserva-
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tive changes p.H2038Y and p.I2282N on the protein level (Figure
S2). We validated the variants by Sanger sequencing. We
subsequently confirmed that all five affected foals were homozy-
gous, while their parents were heterozygous compared to the
reference sequence. We genotyped larger cohorts for these variants
and noticed perfect linkage disequilibrium between the two
variants in more than 300 investigated horses. We were unable
to reliably genotype the c.6112C.T variant from our paraffin-
embedded formalin-fixed and other low quality DNA samples.
Therefore, we then genotyped only c.6845T.A in a very large
cohort of more than 2,300 horses. We observed a strong, but not
perfect association between c.6845T.A variant and the congen-
ital hepatic fibrosis phenotype. We had 1 histopathologically
confirmed case that carried the variant only in heterozygous state
and we had 3 Franches-Montagnes horses that were homozygous
for the variant, but did not show any clinical symptoms up to at
Figure 1. Congenital liver fibrosis in Franches-Montagnes horses. (A) Affected, 2 month old foal. The foal was small for its age and displayed
a potbelly. (B) Enlarged and grey colored liver of the affected foal with macroscopically visible cysts. (C) Histological image of liver tissue from a foal
with congenital hepatic fibrosis. Note the marked porto-portal bridging fibrosis and the abundant dilated bile ductules surrounded by some
inflammatory cells within the fibrotic tissue (H&E, 400x). (D) Histological image of liver tissue from a non-affected foal. Note the small bile ducts in the
portal areas and the absence of fibrosis (H&E 400x).
doi:10.1371/journal.pone.0110125.g001
Figure 2. Pedigree of five Franches-Montagnes horses with congenital hepatic fibrosis. Males are represented by squares, females by
circles. Affected animals are shown with black filled symbols, the year of birth is shown for all animals, and FM laboratory numbers are given for
animals from which DNA was available. The causative genetic defect was probably mainly spread into the population by the stallion Elu born in 1964.
All affected foals are inbred to this stallion and have him both as paternal and maternal ancestor.
doi:10.1371/journal.pone.0110125.g002
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Figure 3. Mapping of congenital hepatic fibrosis to chromosome 20 with 5 cases and 12 controls. (A) Manhattan plot of the genome-
wide allelic association study (GWAS). (B) Detailed view of the associated region. A single SNP at position 49,643,575 exceeded the genome-wide
significance threshold. (C) Homozygosity mapping. The blue bars represent homozygous regions with shared alleles in the 5 affected foals. The
common identical by descent segment among the 5 affected animals delineates a critical interval ranging from Chr20:49,164,218–50,115,936.
doi:10.1371/journal.pone.0110125.g003
Table 1. Non-synonymous variants in the critical interval with respect to the EquCab 2 reference assembly of an affected
Franches-Montagnes horse.
Position on chr.
20
Reference
allele Variant allele Gene Variant (cDNA) Variant (protein)
49,398,500 C T PKHD1 c.10796G.A p.R3599H
49,398,692 A C PKHD1 c.10604T.G p.L3535R
49,597,760 A T PKHD1 c.6845T.A p.I2282N
49,630,834 G A PKHD1 c.6112C.T p.H2038Y
49,630,951 T C PKHD1 c.5995A.G p.K1999E
49,709,730 C A PKHD1 c.4462T.G p.A1488S
49,709,928 C T PKHD1 c.4264G.A p.D1422N
49,710,356 G C PKHD1 c.3836C.G p.A1279G
49,710,359 C T PKHD1 c.3833G.A p.R1278Q
49,710,363 A G PKHD1 c.3829T.C p.S1277P
49,710,468 C T PKHD1 c.3724G.A p.E1242K
49,740,355 C T PKHD1 c.1811G.A p.R604Q
49,741,254 C T PKHD1 c.1670G.A p.R557Q
49,766,468 T C PKHD1 c.317A.G p.E106G
50,077,556 G GC EFHC1 Probable error in the reference assembly
50,077,559 G GC EFHC1 Probable error in the reference assembly
doi:10.1371/journal.pone.0110125.t001
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least an age of 6 years (Table 2). Based on the perfect linkage
disequilibrium observed between c.6112C.T and c.6845T.A,
we speculate that the c.6112C.T variant would show the same or
a highly similar association result (Table S2). We also encountered
a New Forest Pony that was homozygous for both variants and not
reported to show any signs of liver disease.
As we did not find any non-synonymous variant with perfect
association we then also investigated all other variants in the
critical interval. The sequenced affected foal carried a total of
2,048 homozygous sequence variants compared to the reference
genome (including the 16 non-synonymous variants of Table 1).
The sequenced obligate carrier was heterozygous for 471 of these.
Excluding variants that were homozygous in any of the 46 control
genomes further reduced this list down to 64 variants (Table S2).
Only one of these 64 variants was exclusively present in Franches-
Montagnes horses. This variant, a single base transition, was
located in the middle of an intron of PKHD1 more than 4 kb
away from the next exon boundary. We genotyped this variant in
a large cohort of horses and found 3 cases, which were not
homozygous for this variant compared to only 1 for the two non-
synonymous PKHD1 variants (Table 2).
As the horse genome reference sequence contains three gaps in
the PKHD1 gene we amplified these regions by PCR and
analyzed the obtained products by Sanger sequencing. The
comparison of data from affected and non-affected horses revealed
no indication for additional variants located in these regions.
RNA-seq and RT-PCR transcript analyses in liver
We then tested whether a non-coding variant or a variant in an
unknown exon of the PKHD1 gene might be responsible for the
disease. Therefore, we performed an RNA-seq experiment using
liver RNA from an affected and a control horse. We mapped the
reads to the reference genome and produced a gene annotation of
the equine PKHD1 gene (Table S3). For numbering the exons in
the horse genome we used the human PKHD1 transcript isoform
1 as reference, which is derived from 67 exons in the human
genome. All but one of the 67 human exons were also present in
the horse. The human exon 42 was absent in the equine liver
RNA-seq data and could also not be amplified by RT-PCR.
We additionally identified spliced reads indicating the presence
of 9 previously unknown exons in the horse (Table S3). No disease
associated sequence variant was located within these newly
identified PKHD1 exons. All 75 horse specific PKHD1 exons
were transcribed in both, the affected and the control animal. We
did not assign the newly identified exons to different PKHD1
transcripts as the PKHD1 gene obviously encodes a variety of
alternative spliced variants [5]. We also amplified approximately
90% of the PKHD1 coding sequence as overlapping RT-PCR
products from liver RNA of the case and the control. Subsequent
Sanger sequencing of these RT-PCR products confirmed the
results obtained by RNA-seq and did not indicate any structural
defect in the PKHD1 transcript from the affected horse.
Allele specific transcript quantification in an obligate
carrier
As we could not identify a perfectly associated non-synonymous
variant we investigated whether PKHD1 transcripts of the disease-
associated allele and the wildtype allele were present in equal
amounts in an obligate carrier. We obtained a liver biopsy from an
obligate carrier and compared the ratios between the two alleles
from genomic DNA and from cDNA obtained by RT-PCR from
liver RNA. This experiment confirmed the presence of approx-
imately equal amounts of transcripts from both alleles (Figure 4).
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Discussion
Despite the successful mapping of the locus for congenital
hepatic fibrosis in Franches-Montagnes horses to a genomic region
containing a plausible functional candidate gene we could not
identify a perfectly associated sequence variant.
If the phenotype in these horses is indeed caused by a defect in
the PKHD1 gene, it could either be a non-synonymous variant
directly affecting the protein function or a non-coding regulatory
variant affecting gene expression. We have systematically evalu-
ated all non-synonymous variants and found two strongly
associated variants, but for both of these variants we found rare
non-affected horses that were also homozygous for these variants.
Due to the strong association the c.6845T.A variant is currently
used in marker-assisted selection for breeding decisions. Approx-
imately 14% of the current Franches-Montagnes population are
heterozygous for this variant and matings between heterozygous
animals are currently forbidden. It has to be cautioned that not all
exons of the PKHD1 gene are known, but we evaluated at least all
transcribed regions that we could identify after an RNA-seq
experiment from liver RNA.
We also tried to systematically investigate all non-coding
variants in the critical interval, which is of course challenging
due to the size of the investigated region and an imperfect equine
reference genome. Our data argue quite strongly against a
regulatory causative variant for two reasons: On the one hand we
did not find any variants that were stronger associated than the
two non-synonymous variants. We only found one intronic variant
with strong association, which was also private to the Franches-
Montagnes breed. However, this variant was heterozygous in 2 of
our cases, which were homozygous for both of the non-
synonymous variants. This suggests that this intronic variant
originated very recently by a mutation event on the disease-
associated haplotype after it acquired the disease-causing muta-
tion. On the other hand the quantitative analysis of allele-specific
PKHD1 transcripts from a heterozygous carrier animal did not
show large differences in the amount of PKHD1 mRNA from
either the wildtype or the disease-associated allele, which also
strongly argues against a regulatory variant affecting transcription.
These findings emphasize that congenital hepatic fibrosis in the
Franches-Montagnes horses is probably not inherited in a strictly
monogenic autosomal recessive mode with full penetrance.
Possibly one or both of the associated missense sequence variants
are pathogenic but not fully penetrant, e.g. due to unknown
epistatic interactions in the genome.
Among more than 2,300 tested horses we only found 5 horses,
which carried the potentially pathogenic variants in homozygous
state and were not clearly affected. One of these horses was a
Franches-Montagnes foal in a prospective cohort. It was carefully
and repeatedly examined by clinical specialists until the age of 6
months without any signs of disease. A liver ultrasound at the age
of 6 months was completely normal. The owners were asked to
report any changes in the health status to us immediately.
However, when we wanted to re-examine this foal at 12 months of
age, the owners told us that they had it slaughtered in the
meantime. We suspect that this horse was affected with a very late
onset of disease or that disease was suppressed by hypothetical
modifier gene(s). The remaining four discrepant horses were 3
adult Franches-Montagnes horses and one adult New Forest Pony,
where the owners did not report any overt clinical signs. We
speculate that liver disease in these horses has again been
suppressed by hypothetical modifier gene(s).
Finally, we had one Franches-Montagnes foal that had the
typical clinical symptoms of congenital hepatic fibrosis, but carried
only one copy of the disease associated haplotype. We speculate
that this horse might have acquired a second independent
pathogenic mutation on the other PKHD1 allele. However,
unfortunately, the DNA of this animal was of insufficient quality
for a whole genome sequencing experiment and therefore we are
unable to confirm this hypothesis.
In conclusion, this study provides a naturally occurring large
animal model for the liver-restricted subtype of human ARPKD.
The horse phenotype is strongly associated with variants at the
PKHD1 gene. This study highlights that the identification of
causative mutations for Mendelian traits remains a challenging
task, if the underlying variants are located in non-coding regions or
poorly annotated genes. The imperfect genotype-phenotype
correlation possibly suggests the presence of additional modifier
genes. The knowledge of disease linked SNPs allows indirect
selection towards eradication of the disease from the Franches-
Montagnes horse breed.
Materials and Methods
Ethics Statement
All animal work has been conducted according to national
guidelines for animal welfare. The collection of the liver biopsy
from a non-affected horse was approved by the canton of Bern
(permit number BE114/12). The collection of blood samples from
non affected horses was approved by the canton of Vaud (permit
no. 2227). Blood samples from the CLF affected horses were taken
for diagnostic purposes. Liver samples from CLF affected horses
were taken post mortem. Thus the sample collection from CLF
affected horses did not constitute an animal experiment and
required no extra permit. All samples were taken with the owners’
consent or were voluntarily submitted by the owners for diagnostic
purposes. CLF affected horses were either slaughtered (slaughter-
Figure 4. Allele-specific quantification of PKHD1 transcripts. We
sequenced a PCR product derived from genomic DNA and an RT-PCR
product derived from liver RNA of a heterozygous stallion, which had
already sired an affected foal and was therefore considered an obligate
carrier of the disease causing variant. The electropherograms show
comparable ratios of both alleles on genomic DNA and cDNA. This
indicates that both alleles are transcribed at similar levels and that there
is no nonsense-mediated decay of the transcript derived from the
disease-associated A-allele.
doi:10.1371/journal.pone.0110125.g004
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house Thun), euthanized due to humane reasons, or died as a
result of their disease. No animal was sacrificed for this study.
The protocol for euthanasia of CLF affected foals involved
sedation of the mare by intravenous injection of 1 mg/kg xylazine,
if the foal was still with the mare. Subsequently, an intravenous
catheter was placed into the jugular vein of the foal with lidocaine
anesthesia at the placement site. The foal was then sedated by
injection of 1 mg/kg xylazine into the catheter. Approximately
5 minutes after the sedation injection, the mare was separated
from the foal and the CLF affected foal was euthanized by
injection of 90 mg/kg pentobarbital into the catheter.
Animal selection
A total of 2,123 Franches-Montagnes horses were investigated
in this study. These included a total of 25 cases affected with
congenital hepatic fibrosis and at least some DNA for genetic
analysis available. The samples of the cases were collected over a
period of 30 years (1984–2013) and include e.g. paraffin
embedded formalin-fixed liver tissue samples animals from
histopathological analyses of old cases.
Our cohort included 2,098 Franches-Montagnes horses that we
considered as non-affected control horses. These included 173
healthy Franches-Montagnes older than 5 years with no report of
liver disease until the time point of sampling. The other 1,925
Franches-Montagnes were either younger than 5 years, or no
information about age or health status was available.
We additionally used 234 non-affected horses from genetically
diverse horse breeds (Table S1, Table S2).
DNA isolation and SNP genotyping
We isolated genomic DNA from EDTA blood and tissue
samples with the Nucleon Bacc2 kit (GE Healthcare). The
isolation of genomic DNA from paraffin embedded tissue samples
was carried out using the DNeasyBlood & Tissue Kit (QIAGEN)
combining the protocol for pretreatment for paraffin embedded
tissue and the spin-column protocol for purification of total DNA
from animal tissue as recommended by the manufacturer. The
DNA of 5 recent cases with good DNA quality and 12 controls was
genotyped by GeneSeek with the EquineSNP70 Genotyping
BeadChip (Illumina) including 65,157 evenly distributed SNPs.
Genome-wide association and homozygosity mapping
We used PLINK v1.07 [19] to perform genome-wide associa-
tion analyses (GWAS). All 5 cases and 12 controls used for the
analysis had call rates .90%. We removed markers with call rates
,90% and with minor allele frequency (MAF),5%. All remain-
ing markers were in Hardy-Weinberg equilibrium (p.1025). The
final dataset consisted of 17 horses and 38,394 SNPs. We
performed an allelic association study and determined an
empirical significance threshold by performing 100,000 permuta-
tions of the dataset with arbitrarily assigned phenotypes.
We analyzed regions of shared homozygosity among the 5 cases
on chromosome 20 by visual inspection of the genotypes in an
Excel-file. We also performed a homozygosity search with PLINK
v1.07 using the following parameters: –homozyg –homozyg-group
–homozyg-kb 500 –homozyg-snp 25 –homozyg-match 0.95 –
homozyg-het 1. The homozygous region on chromosome 20 was
the only region in the entire genome that fulfilled our search
criteria using these parameters.
Whole genome re-sequencing
We prepared fragment libraries with a 200 bp–300 bp insert
size and collected one lane of illumina HiSeq2000 paired-end
reads (26100 bp) per genome. Fastq files were created using
Casava 1.8. We obtained a total of 234,536,171 (affected horse)
and 568,567,625 (carrier) paired-end reads which were then
mapped to the horse reference genome Broad/equCab2.0 and
aligned using Burrows-Wheeler Aligner (BWA) version 0.5.9-r16
[20] with default settings. The mapping showed 204,062,157 and
517,388,289 reads had unique mapping positions revealing
roughly a 7.55x and 19.1x coverage, respectively. The SAM file
generated by BWA was then converted to BAM and the reads
sorted by chromosome using samtools (http://samtools.
sourceforge.net/). PCR duplicates were marked using Picard tools
(http://sourceforge.net/projects/picard/). We used the Genome
Analysis Tool Kit (GATK version 2.4.9, [21]) to perform local
realignment and to produce cleaned BAM files. Variant calls were
then made with the unified genotyper module of GATK. We also
performed a visual inspection of the aligned reads in the
integrative genomics viewer (IGV, [22]) to search for large
structural variants. However, this analysis did not indicate any
structural variation within the critical interval.
The variant data for each sample was obtained in variant call
format (version 4.0) as raw calls for all samples and sites flagged
using the variant filtration module of GATK. Variant filtration
was done following best practice documentation of GATK version
4. The snpEFF software [23] together with the Broad/equCab2.0
Ensembl annotation version 2.69 was used to predict the
functional effects of detected variants.
RNA sequencing
We isolated total RNA from the liver of an affected and a non-
affected horse and prepared two fragment libraries with 350 bp
insert size following illumina’s TruSeq mRNA Sample Preparation
Guide and collected half of a lane of illumina HiSeq2000 paired-
end reads (26100 bp) per library obtaining 152,265,046 (affected
horse) and 121,033,908 tags (non-affected horse). We mapped the
reads to the horse reference genome (Broad/equCab2.0) using the
spliced alignment program TopHat2 with default parameters [24].
Read counting and differential gene expression analysis was
performed using Cufflinks 2.0 software [25].
RT-PCR
Using the same liver RNA samples described above we also
amplified the PKHD1 cDNA from position 252 to +10706 as a
series of 9 overlapping RT-PCR products using SuperscriptII
(LifeTechnologies) and AmpliTaqGold360 Mastermix (Life Tech-
nologies) according to the manufacturer’s recommendations. A
transcript containing the complete equine PKHD1 coding
sequence was assembled from the RNA-seq data and Sanger
sequences derived from the RT-PCR products (Figure S3).
Sanger sequencing
The associated variants were genotyped by re-sequencing of
targeted PCR products using Sanger sequencing technology. PCR
products were amplified using AmpliTaqGold360 Mastermix (Life
Technologies) and the products were directly sequenced on an
ABI 3730 capillary sequencer (Life Technologies) after treatment
with exonuclease I and shrimp alkaline phosphatase. Sequence
data were analyzed with Sequencher 5.1 (GeneCodes).
Supporting Information
Figure S1 Alignment of the human PKHD1 protein
(NP_619639.3) to the equine PKHD1 protein derived
from a non-affected horse (translated from the sequence
given in Figure S3).
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(DOCX)
Figure S2 Conservation of the histidine residue at
position 2038 and the isoleucine residue at position
2282 in the PKHD1 protein.
(DOCX)
Figure S3 Sequence of a predicted equine PKHD1
transcript, which was assembled from Sanger-se-
quenced RT-PCR products and RNA-seq data. This
assembled mRNA sequence was derived from different horses
and does not necessarily resemble one contiguous haplotype.
(TXT)
Table S1 Horses used for whole genome sequencing.
(DOCX)
Table S2 Genotypes of 64 variants in the critical
interval, which were homozygous variant in the se-
quenced genome of an affected Franches-Montagnes foal
and either homozygous wildtype or heterozygous in the
genome sequences of 29 non-affected Franches-Mon-
tagnes horses and 18 non-affected horses from other
breeds.
(DOCX)
Table S3 Equine PKHD1 annotation.
(XLSX)
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